NasdaqCM - Nasdaq Real Time Price USD

Virax Biolabs Group Limited (VRAX)

Compare
4.6600 -0.4000 (-7.91%)
At close: August 30 at 4:00 PM EDT
4.6600 0.00 (0.00%)
After hours: August 30 at 7:59 PM EDT
Loading Chart for VRAX
DELL
  • Previous Close 5.0600
  • Open 5.2300
  • Bid 4.7400 x 3800
  • Ask 5.4400 x 100
  • Day's Range 4.6400 - 5.5200
  • 52 Week Range 0.6000 - 9.0000
  • Volume 2,165,740
  • Avg. Volume 5,566,436
  • Market Cap (intraday) 20.234M
  • Beta (5Y Monthly) 1.56
  • PE Ratio (TTM) --
  • EPS (TTM) -3.3600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.

viraxbiolabs.com

17

Full Time Employees

March 31

Fiscal Year Ends

Recent News: VRAX

View More

Performance Overview: VRAX

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

VRAX
219.18%
S&P 500
18.42%

1-Year Return

VRAX
25.95%
S&P 500
25.59%

3-Year Return

VRAX
97.67%
S&P 500
41.25%

5-Year Return

VRAX
97.67%
S&P 500
41.25%

Compare To: VRAX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VRAX

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    20.67M

  • Enterprise Value

    17.30M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    61.06

  • Price/Book (mrq)

    3.85

  • Enterprise Value/Revenue

    110.62

  • Enterprise Value/EBITDA

    0.42

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -49.90%

  • Return on Equity (ttm)

    -95.98%

  • Revenue (ttm)

    156.42k

  • Net Income Avi to Common (ttm)

    -6.73M

  • Diluted EPS (ttm)

    -3.3600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.67M

  • Total Debt/Equity (mrq)

    4.36%

  • Levered Free Cash Flow (ttm)

    -5.01M

Research Analysis: VRAX

View More

Company Insights: VRAX

Research Reports: VRAX

View More

People Also Watch